Samrat Pharmachem Ltd Stock Price Today (NSE: SAMRATPH)

Samrat Pharmachem Ltd

198.303.30 (1.64%)
Market Closed

Fundamental Score

...

Samrat Pharmachem Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Samrat Pharmachem Ltd share price today is 198.30, down 1.64% on NSE/BSE as of 17 June 2026. Samrat Pharmachem Ltd (SAMRATPH) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of 75.79 (Cr). The 52-week high for SAMRATPH share price is 389.00 and the 52-week low is 190.00. At a P/E ratio of 48.58x, SAMRATPH is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 10.07% and a debt-to-equity ratio of 0.15.

Samrat Pharmachem Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
241.00
Low
198.30
Volume
1.9K
Change
+7.83%

Samrat Pharmachem Ltd share price chart: 7.83% return over the past month. 52-week high ₹389.00, 52-week low ₹190.00.

Samrat Pharmachem Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
233.70238.80220.00225.90849.00 (Cr)
231.85238.25230.00232.551.30K (Cr)
230.00241.00230.00232.252.76K (Cr)
221.05225.85221.00224.551.01K (Cr)
208.60234.00208.55222.008.59K (Cr)
213.95213.95208.00208.55105.00 (Cr)
212.00213.95202.00213.351.47K (Cr)
208.00216.85208.00212.70477.00 (Cr)
210.00217.80207.00209.502.08K (Cr)
212.95218.95208.10208.60847.00 (Cr)

Samrat Pharmachem Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
215.05241.00202.00225.90+5.05%
198.95230.80192.65211.10+6.11%
200.00243.85190.00194.95-2.53%
203.50255.60200.00209.40+2.90%
234.50238.00195.10200.50-14.50%
250.00270.00224.00227.30-9.08%
290.85294.70251.00255.40-12.19%
297.00320.00271.10290.85-2.07%
320.25333.00289.00291.50-8.98%
340.00355.00314.00324.95-4.43%
359.00389.00340.00342.95-4.47%
331.00378.95331.00358.85+8.41%

Returns & Performance

Poor

Return on Equity (ROE)

10.07%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

13.21%

Returns generated on total capital deployed

Poor

Oper. Profit Margin (5Y Avg)

5.45%

Average operating profit margin over 5 years

Dividend Yield

0.41%

Annual dividend as % of current share price

Samrat Pharmachem Ltd Valuation Check

Poor

Price to Earnings (P/E)

48.58x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

31.77x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

49.09%

% shares held by company founders/management

Poor

FII Holding

3.24%

% shares held by foreign institutional investors

Poor

DII Holding

0.00%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

-122.18%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

12.40%

Revenue growth vs same quarter last year

Excellent

Revenue Growth (5-Year CAGR)

15.77%

Compounded annual revenue growth over 5 years

Average

EPS Growth (5-Year CAGR)

10.15%

Earnings per share growth over 5 years

Average

Net Profit Growth (5-Year CAGR)

10.15%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.15x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

3.95x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

6.78 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Samrat Pharmachem Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of SAMRATPH across key market metrics for learning purposes.

Positive Indicators

3 factors identified

Consistent Growth Track Record (15.77% CAGR)

Observation: Strong 5-year sales compound annual growth rate.

Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.

Conservative Debt Levels (D/E: 0.15)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

3 factors identified

Premium Valuation Risk (P/E: 48.58x)

Observation: High valuation multiples may limit upside potential.

Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.

Profit Decline Concern (-122.18%)

Observation: Significant year-over-year profit contraction observed.

Analysis: Declining profitability requires investigation into underlying causes.

Limited Institutional Interest (FII+DII: 3.24%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

Samrat Pharmachem Ltd vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Samrat Pharmachem Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
38.1/100
198
₹75.79
48.6
Average
10.07%
Average
13.21%
Average
0.1
Excellent
10.15%
Good
15.77%
Excellent
0.41%
65.2/100
1882
₹433738.68
37.6
Average
16.86%
Good
20.21%
Excellent
0.1
Excellent
23.78%
Excellent
9.87%
Good
0.89%
67.9/100
6798
₹170445.88
68.6
Average
15.35%
Good
20.44%
Excellent
0.0
Excellent
10.41%
Good
11.65%
Good
0.47%
65.3/100
4460
₹126430.62
58.4
Average
26.52%
Excellent
27.05%
Excellent
0.3
Excellent
13.84%
Good
7.72%
Good
0.86%
Cipla Ltd...
CIPLA500087
59/100
1418
₹123059.76
22.6
Average
17.77%
Good
22.72%
Excellent
0.0
Excellent
28.68%
Excellent
9.97%
Good
0.85%
59.2/100
1335
₹105224.96
18.2
Average
17.96%
Good
22.69%
Excellent
0.2
Excellent
22.28%
Excellent
13.26%
Good
0.63%
Lupin Ltd...
LUPIN500257
66.7/100
2287
₹95148.15
22.0
Average
20.62%
Excellent
21.30%
Excellent
0.3
Excellent
54.88%
Excellent
8.11%
Good
0.58%
68.7/100
957
₹94253.78
18.7
Average
21.21%
Excellent
24.31%
Excellent
0.4
Excellent
25.92%
Excellent
10.27%
Good
1.17%
50.6/100
2493
₹92012.53
52.6
Average
14.68%
Average
15.98%
Good
0.6
Good
11.73%
Good
15.79%
Excellent
0.04%
28.8/100
1436
₹70798.69
20.7
Average
11.08%
Average
14.18%
Average
0.2
Excellent
3.87%
Average
6.55%
Good
0.33%
59.5/100
5452
₹67075.29
28.5
Average
19.39%
Good
20.38%
Excellent
0.2
Excellent
13.93%
Good
9.21%
Good
0.80%

Samrat Pharmachem Ltd PE Ratio History

Historical price-to-earnings ratio for SAMRATPH — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 20247.00₹382.6554.7x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Samrat Pharmachem Ltd Dividend History

Annual cash dividends paid by SAMRATPH — dividend yield 0.41%

Financial YearDividends Paid (₹ Cr)
FY 20250.31 Cr
FY 20240.31 Cr
FY 20230.31 Cr

Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.

Samrat Pharmachem Ltd Quarterly Performance

Latest quarterly metrics for SAMRATPH — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

12.40%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

-122.18%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

15.77%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

10.15%

Compounded annual net profit growth over 5 years

Samrat Pharmachem Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for SAMRATPH — calculated from daily price history

54RSI 14
Neutral — RSI 54

Momentum is balanced — neither overbought nor oversold.

SMA 50
212
▼ Price below SMA 50 — Short-term bearish
SMA 200
254
▼ Price below SMA 200 — Long-term downtrend
30-Day Avg Volume
2K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Samrat Pharmachem Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Samrat Pharmachem Ltd (SAMRATPH) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Samrat Pharmachem Ltd

About SAMRATPH (Samrat Pharmachem Ltd)

Samrat Pharmachem Ltd is a stalwart in the Indian pharmaceutical landscape, deeply rooted in the production and distribution of a diverse array of pharmaceutical chemicals. Their o...perations hum with a precision that reflects decades of experience, crafting specialized iodine-based compounds and related substances vital to numerous sectors. Think of them as the silent engine providing the essential building blocks for medications, diagnostic tools, and research applications across the nation and beyond. Samrat Pharmachem doesn't directly create finished medicines, but their contribution is indispensable, ensuring a steady and reliable supply of high-quality chemical ingredients that underpin the medical industry. The company's portfolio is a testament to their mastery of iodine chemistry, encompassing a wide spectrum of iodides, iodates, and related compounds. They meticulously synthesize everything from the foundational hydroiodic acid and elemental iodine to more complex molecules like clioquinol and iodoquinol, each meticulously tested and refined to meet stringent industry standards. Their product list is not exhaustive, it includes various metallic iodides like copper iodide and cadmium iodide, alongside organic iodides such as ethyl iodide and methyl iodide. Samrat Pharmachem also demonstrates its ability to cater to diverse needs with offerings like povidone iodine, commonly found in antiseptic solutions, highlighting their dedication to serving a broad range of pharmaceutical requirements. Samrat Pharmachem Ltd functions as a cornerstone in the supply chain, providing the raw materials that empower pharmaceutical companies to develop and manufacture life-saving and life-improving medications. They are the unsung heroes who contribute to advancements in healthcare with their dedication to chemical excellence. Their sustained success lies in their capacity to consistently deliver quality products, establishing them as a trusted and dependable partner for pharmaceutical manufacturers throughout India and in select international markets. The company's presence ensures the continuous availability of vital chemical substances and supports the growth and development of the wider pharmaceutical industry.

Company Details

Symbol:SAMRATPH
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Lalit Damodar Mehta
Founder, Chairman, CEO & MD
Mr. Rajesh Lalit Mehta B.Com, CA
CFO & Non-Independent Executive Director
Mr. Nishant Kankaria
Company Secretary & Compliance Officer

Corporate Events

Recent
Ex-Dividend Date

SAMRATPH Share Price: Frequently Asked Questions

What is the current share price of Samrat Pharmachem Ltd?

Samrat Pharmachem Ltd (SAMRATPH) trades at ₹198.30 on NSE and BSE. Market cap ₹75.79 (Cr). Educational data only.

What is the P/E ratio of Samrat Pharmachem Ltd?

Samrat Pharmachem Ltd has a P/E of 48.58x vs industry average 31.77x.

What is the Bull Run score for Samrat Pharmachem Ltd?

Samrat Pharmachem Ltd has a Bull Run score of 38.1/100 based on 25+ financial parameters.

Does Samrat Pharmachem Ltd pay dividends?

Samrat Pharmachem Ltd has a dividend yield of 0.41%. Past dividends don't guarantee future payments.

What is the ROE of Samrat Pharmachem Ltd?

Samrat Pharmachem Ltd has ROE of 10.07%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Samrat Pharmachem Ltd?

Samrat Pharmachem Ltd has debt-to-equity of 0.15.

Is Samrat Pharmachem Ltd a good investment?

Bull Run gives Samrat Pharmachem Ltd a score of 38.1/100. This is not investment advice — consult a SEBI-registered advisor.